Pressemitteilung BoxID: 520375 (SIRION BIOTECH GmbH)
  • Am Klopferspitz 19
  • 82152 Martinsried
  • Ansprechpartner
  • Dieter Lingelbach
  • +49 (89) 70096199-14

SIRION Biotech to present at prestigious World Summit on Innovation and at Seed4Money Investors' forum

SIRION BIOTECH invited to Frankfurt on 03 July 2012 and to Boston on 26 September 2012

(PresseBox) (Martinsried, ) SIRION Biotech is invited to present its business model and its recent history of success at the World Summit on INNOVATION & ENTREPRENEURSHIP in Boston on 26 - 28 September 2012: "The Summit sets the scene for some of the world's eminent dreamers and doers to plot the new frontier of the smarter innovation economy" ( The World Summit on Innovation & Entrepreneurship was launched in 2006 at the United Nations under the support of three UN agencies, International Chamber of Commerce, African Union, in partnership with key multinationals like PepsiCo, Cisco, La Post, Boeing, Microsoft, CNBC, and Business Week. The Summit connects an elected group of the world's most innovative people to exchange inspiring stories and architect meaningful actions for economic competitiveness and social innovation.

SIRION Biotech will also present at the 11th Seed4Money Investors' Forum at the Frankfurt Stock Ex-change on 03 July 2012. The event is being hosted by Science4Life, a renowned initiative for found-ers in the Life and Chemistry Sciences since 1998.


SIRION BIOTECH GmbH is a biotech company that produces genetically modified cells and is a tech-nology provider in the area of viral vector systems for gene therapy and vaccine applications. The company was founded in 2006 and is located in Munich with offices in Tokyo and New Hampshire. The expert in RNAi technology offers a wide range of more than 100 products and services. Using state of the art techniques and assay systems the company offers reliable lead-through service pro-jects in target validation, screening and discovery for the drug, food & cosmetic industries.

SIRION BIOTECH currently operates projects for most of the major pharmaceutical companies in Europe and has ongoing collaborations with leading academic and governmental research institutes. Increasingly, clients from Japan and USA are being served.